Status: Recruiting
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Updated: Sep 17, 2025Locations: 6
Eligibility criteria
Estimated glomerular filtration rate (eGFR) >30 milliliters/minute/1.73 square m... [+6]
Receipt of high-dose corticosteroid therapy within 4 weeks prior to screening as... [+10]